A Clinical Study of Nasya and Rasayan in Post COVID-19 Syndrome

A Clinical Study of Nasya and Rasayan in Post COVID-19 Syndrome Specifically on its Symptoms and Functional Status Scale

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036318

Enrollment

Registered

2021-09-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 3: B342- Coronavirus infection, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient willing and able to participate in the study. 2.COVID-19 positive patients after 21 days up to one year from the date of positive report. 3.Patients presenting with minimum 20% (at least 4) symptoms of Post COVID 19 Syndrome. 4.Functional Status Scale grading between 1 to 4 will be taken 5.Patients who are suitable for Nasya. 6.Patients who had not participated in any research projects since last 6 months. 7.Patients irrespective of sex, socio-economical status and religion aged between 18-70 years. 8.Patients of Post COVID 19 Syndrome having controlled hypertension 9.(BP 10.Patients who follows instructions advised by researcher strictly.

Exclusion criteria

Exclusion criteria: 1)Patient not willing for trial. 2)Patient having severe disease with complication like AIDS, Cardiovascular disease, Pulmonary disease, Tuberculosis, malignancy will be rejected 3)Patients having gross disability in performing daily normal routine i.e. bed ridden patients or confined to a wheelchair. 4)Patients with poorly controlled Hypertension and Diabetes Mellitus 5)Patients who are currently participating in any other clinical trials (since last 6 months). 6)Patients contraindicated for Nasyaas mentioned in classics.[18] 7)Patient who do not follow instruction strictly. 8)Pregnant females and lactating mothers.

Design outcomes

Primary

Measure	Time frame
1.To study the effect of Bhargyadi Tail Nasya followed by Ashwagandha Kshirpaak and Guduchi Ghana Vati in Post COVID-19 Syndrome on itssymptoms. 2.To study the effect of Bhargyadi Tail Nasya followed by Ashwagandha Kshirpaak and Guduchi Ghana Vati in Post COVID-19 Syndrome on Functional Status Scale . Timepoint: 33 days	—

Secondary

Measure	Time frame
To study Abhishangaja Jirna Jvara with reference to Post COVID-19 Syndrome.Timepoint: 33 days	—

Countries

India

Contacts

Public ContactAshish Thatere

Government Ayurved College, Nagpur

ashish.thatere@gmail.com9423406821

Outcome results